Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

EGFR-TKI compound for delaying or reversing drug-resistance in lung cancer treatment, and preparation thereof

A technology of EGFR-TKI and compound, which is applied in the field of tumor drugs, can solve the problems of expensive treatment, achieve the effects of improving curative effect, enhancing sensitivity, and overcoming the shortcomings of easy drug resistance

Active Publication Date: 2013-09-25
THE THIRD AFFILIATED HOSPITAL OF THIRD MILITARY MEDICAL UNIV OF PLA
View PDF1 Cites 12 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] Although the above methods of overcoming EGFR-TKI acquired drug resistance have achieved certain effects, the treatment is expensive, and the effect of overcoming drug resistance still needs to be improved

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • EGFR-TKI compound for delaying or reversing drug-resistance in lung cancer treatment, and preparation thereof
  • EGFR-TKI compound for delaying or reversing drug-resistance in lung cancer treatment, and preparation thereof
  • EGFR-TKI compound for delaying or reversing drug-resistance in lung cancer treatment, and preparation thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0083] Embodiment 1 combined packaging

[0084] The combination pack includes 1 tablet of metformin hydrochloride (each tablet contains 250 mg of metformin hydrochloride) and 1 tablet of erlotinib (each tablet contains 25 mg of erlotinib)

Embodiment 2

[0085] Embodiment 2 combined packaging

[0086] The combination pack includes 1 tablet of metformin hydrochloride (each tablet contains 250 mg of metformin hydrochloride) and 1 tablet of erlotinib (each tablet contains 100 mg of erlotinib)

Embodiment 3

[0087] Embodiment 3 combined packaging

[0088]The combination pack includes 1 tablet of metformin hydrochloride (each tablet contains 250 mg of metformin hydrochloride) and 1 tablet of erlotinib (each tablet contains 150 mg of erlotinib)

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to an application of a biguanide based medicament in medicaments for delaying or reversing acquired drug-resistance of NSELC treated by EGFR-TKI, wherein the biguanide based medicament and EGFR-TKI are taken simultaneously or intervally. The compound is used to delay or reverse generation of EGFR-TKI acquired drug-resistance, and performs varying-degree inhibition effects on main mechanisms of EGFR-TKI acquired drug-resistance of NSCLC patients, and thus the sensibility of the lung-cancer patients to EGFR-TKI is increased, the disadvantage that EGFR-TKI is easy to resist drugs is overcome, and the curative effect of EGFR-TKI is improved.

Description

technical field [0001] The invention belongs to the field of tumor drugs, in particular to an EGFR-TKI compound and a preparation thereof for delaying or reversing acquired drug resistance of non-small cell lung cancer. Background technique [0002] Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) is currently approved by many countries and widely used in advanced or refractory non-small cell lung cancer (non-small cell lung cancer, NSCLC). Small molecule targeted drugs targeting EGFR. One of the bottlenecks restricting the further application of EGFR-TKI is the occurrence of acquired drug resistance. The generation of acquired resistance to EGFR-TKI is related to at least two mechanisms: secondary exon T790M mutation and secondary amplification of MET. Chinese patent CN102626405A discloses the application of paclitaxel in the preparation of drugs for the treatment of EGFR-TKI acquired drug resistance. The invention confirms that paclitaxel can reverse...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K45/00A61K31/517A61K31/519A61K31/5377A61P35/00A61K31/155
Inventor 何勇李力
Owner THE THIRD AFFILIATED HOSPITAL OF THIRD MILITARY MEDICAL UNIV OF PLA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com